Oxford Cancer Analytics (OXcan) has secured $11m in Series A funding for the development of its liquid biopsy blood tests for ...

OXcan was founded in 2020 by Dr. Peter Jianrui Liu and Dr. Andreas Halner to advance early cancer detection using liquid biopsy.

The blood test for those at high risk of lung cancer could lead to earlier detection and a "major reduction" in deaths, a ...

OXcan has also appointed Dr. Heinrich Roder as Senior Vice President, Research & Development. With over two decades of experience in lung cancer liquid biopsy and commercialization, Dr. Roder will ...

This latest investment, which brings OXcan’s total funding to date to $16.7 million, will be used to develop and globally ...

Oxford, UK and Toronto-based OXcan has secured over $11 million USD in Series A funding to develop and deploy its ...

Blood testing people at high risk of lung cancer could reduce the number of deaths, a study has found. University of St ...

The large-scale trial involved 12,208 smokers and ex-smokers who were aged between 50 and 75 years old and at high risk of ...

Biodesix announces positive study data for its Nodify CDT blood-based lung nodule test published in CHEST Pulmonary Journal.

Doctors around the world may soon have access to a new tool that could better predict whether individual cancer patients will ...

The Nodify CDT test measures levels of seven autoantibodies associated with lung cancer that can be detected in blood samples of patients with indeterminate lung nodules. Prior studies have ...